Tirofiban After Rescue therapy in CVA (Failed Stroke Thrombolysis): A New Opportunity, Not a New Standard<\/p>\n
The INSTANT trial reported a higher rate of excellent 90-day recovery (63.8% vs 52.2%) when Tirofiban was given after Tenecteplase in selected ischemic stroke patients who failed to show adequate neurological improvement within 4\u201324 hours, without a significant increase in symptomatic intracranial hemorrhage.<\/p>\n
However, this does not mean Tirofiban should be routinely used after thrombolysis.<\/p>\n
The benefit was observed in a highly selected population:<\/p>\n
\u2022\u2060 \u2060Treated with Tenecteplase.
\n\u2022\u2060 \u2060Poor early clinical response (who failed to show adequate neurological improvement within 4\u201324 hours)
\n\u2022\u2060 \u2060No large-vessel occlusion requiring mechanical thrombectomy.
\n\u2022\u2060 \u2060No cardioembolic stroke, particularly atrial fibrillation.<\/p>\n
Why exclude AF?<\/p>\n
Because AF-related thrombi are typically fibrin-rich, where anticoagulation is the cornerstone therapy. In contrast, non-cardioembolic strokes are often associated with platelet-rich thrombi, making potent platelet inhibition with Tirofiban biologically more relevant.<\/p>\n
For cardiologists, the concept is familiar.<\/p>\n
This is similar to using Tirofiban during primary PCI for STEMI with a large thrombus burden, slow flow, or suboptimal reperfusion. It may be valuable as a bailout or adjunctive strategy, but it is not routinely given to every STEMI patient.<\/p>\n
The same principle applies here.<\/p>\n
The INSTANT trial supports a potential role for Tirofiban as a rescue therapy after inadequate response to thrombolysis in carefully selected stroke patients, rather than as routine treatment for all ischemic strokes.<\/p>\n
At present, the findings are promising, hypothesis-strengthening, and clinically relevant\u2014but not yet practice-changing.<\/p>\n
Source: JAMA, June 9, 2026 (Print Issue); published online May 8, 2026.<\/p>\n